Skip to content

Video-Assisted Thoracoscopic pulmonary vein isolation versus percutaneous Catheter Ablation in atrial fibrillation Trial

Video-Assisted Thoracoscopic pulmonary vein isolation versus percutaneous Catheter Ablation in atrial fibrillation Trial - VATCAT

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39516
Enrollment
160
Registered
2010-07-20
Start date
2010-10-02
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

minimaal invasieve interventie atrial fibrillation

Interventions

Percutaneous catheter ablation (n=104) versus video-assisted epicardial ablation and left atrial appendage exclusion (n=52). 2:1 randomization

Sponsors

Medisch Spectrum Twente
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Patients > 18 years of age * Documented, symptomatic, episodes of paroxysmal or persistent AF * During the last 6 months patients must have at least 2 documented episodes of AF, despite the use of at least 1 anti arrhythmic drug. * Able of providing informed consent

Exclusion criteria

Exclusion criteria: * Pregnancy * Unwillingness to use or contra-indications for vitamin K antagonists * Severely enlarged left atrium (>50 mm) on echocardiography * Prior AF ablation or AF surgery * Intracardiac thrombus * Prior heart surgery or pulmonary disease hampering thoracoscopic surgery

Design outcomes

Primary

MeasureTime frame
The percentage of patients without a recurrence of AF, without AADs, within a follow-up period of at least 12 months after a stabilisation period of 90 days after the initial procedure. An episode of AF is defined as an episode of at least 30 seconds duration.

Secondary

MeasureTime frame
Secondary objectives include the duration and cost of hospitalization, discomfort during admission, assessment and experienced AF burden during follow-up of procedural impact on the patient and time to recurrence after intervention. A complication register will also be kept.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)